Plain-English translation of NCT02573259 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Ovarian cancer research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial tested an experimental medication called designed to help the immune system fight cancer. Researchers studied the medication in patients with advanced solid tumors—including melanoma, lung cancer, ovarian cancer, and others—who had already received standard treatments without adequate benefit. The study examined how safe the medication was, what dose worked best, and whether it could help shrink tumors.
Many patients with advanced cancers stop responding to standard treatments or cannot tolerate them. This medication was being investigated as a potential new option for these patients, with the goal of understanding the right dose and confirming whether this treatment could help control their cancer.
Participants in this trial received the experimental medication either as an intravenous infusion or an injection under the skin, given at different dose levels every 3 or 4 weeks depending on which part of the study they were in. Participants underwent blood tests, scans, and other assessments to monitor how the medication affected their cancer and to watch for any side effects. The trial involved multiple visits to the research center over several weeks to months.
AI-generated summary from trial data · Oct 12, 2026 · Not medical advice
United States